Jan 2026· PPAR Research· Vol 2026· 0 citations· 33 references
Medicine
TL;DR
Targeted metabolomics confirmed seladelpar′s impact on carnitine and acylcarnitines, which facilitate fatty acid β‐oxidation, and highlighted potential pathways for future exploration in the treatment of PBC and its symptoms.
Abstract
Background Seladelpar, a potent and selective peroxisome proliferator‐activated receptor‐δ (PPARδ) agonist, is an approved second‐line therapy for primary biliary cholangitis (PBC) in patients with an inadequate response or intolerance to ursodeoxycholic acid (UDCA). In clinical studies, seladelpar significantly improved biochemical markers associated with disease progression and pruritus. Our objective was to explore the metabolic mechanisms underlying seladelpar′s effects and identify potential biomarkers. Methods Untargeted serum metabolomic analyses were conducted using UHPLC‐MS/MS on fasting samples from 160 patients with PBC, collected before and after 12 weeks of treatment with placebo (n = 55), seladelpar 5 mg (n = 52), or seladelpar 10 mg (n = 53) in a randomized, placebo‐controlled Phase 3 study (NCT03602560). Results A total of 1474 metabolites were identified from global untargeted serum metabolomics analysis. Random forest, weighted correlation network analysis, and differential abundance analysis revealed significant metabolomic changes after seladelpar treatment. Notable changes included significant increases in carnitine, acetylcarnitine, other acylcarnitines, and branched‐chain amino acid catabolites as well as significant decreases in dicarboxylates, saturated and unsaturated fatty acids, and lipid‐derived inflammatory mediators including ceramides. Targeted metabolomics confirmed seladelpar′s impact on carnitine and acylcarnitines, which facilitate fatty acid β‐oxidation. Gene expression analysis of primary human hepatocytes and mouse tissues showed upregulation of carnitine transporter and mitochondrial carnitine shuttle genes with seladelpar treatment. Conclusions Seladelpar treatment of PBC patients resulted in broad changes in serum metabolites, many of which are downstream of known PPARδ activation effects, including peroxisomal and mitochondrial fatty acid β‐oxidation. This comprehensive metabolomics analysis highlights potential pathways for future exploration in the treatment of PBC and its symptoms. Trial Registration: ClinicalTrials.gov identifier: NCT03602560; EudraCT number: 2018‐001171‐20
Metabolic dysfunction-associated steatohepatitis (MASH) represents a significant global health burden, affecting 3-5% of the population and projected to become a leading cause of liver transplantation by 2030. This review examines Resmetirom, the first FDA-approved drug for non-cirrhotic MASH with moderate to severe he...
Ghulam Hassam U. Din Tarrar, Syed Shafaat Hussain, M. Sarfraz et al.· Prague Medical Report· 0 citations
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to metabolic syndrome and to thyroid dysfunction, particularly hypothyroidism, which may weaken Thyroid Hormone Receptor-β (THR-β) signaling in hepatocytes. Resmetirom, an oral liver-directed THR-β agonist, is the first drug...
Girin Ray, D. Sanyal· Archives of Endocrinology an...· 0 citations
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), is associated with substantially elevated cardiovascular risk, yet the cardiovascular efficacy of antidiabetic drugs in this population has not been systematically quant...
Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters, and this findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowerin...
Andrea Sorrentino· Bleeding Thrombosis and Vasc...· 0 citations
Objective To characterize the clinical, gut microbial, and serum metabolic features of uric acid nephropathy (UAN) and identify candidate metabolic signatures distinguishing UAN from uncomplicated hyperuricemia (HUA). Methods This observational study enrolled 108 patients with hyperuricemia, including 57 with HUA and 5...
Min Cui, Sheng Li, Chen-Yu Wang et al.· Frontiers in Microbiology· 0 citations
Human genetic evidence supports hepatic iron lowering by TMPRSS6 inhibition, but not an effect on steatosis, and the CAD signal, partly mediated by LDL cholesterol, warrants careful consideration in trial design.
M.-J. Dib, M. Vujkovic, S. Burgess et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.